Odisha’s First Vaccine Manufacturing Plant ‘Sapigen Biologix’ To Start Production By May 2024

Bhubaneswar: Commercial production at the Sapigen Biologix vaccine plant in Odisha, the first such facility in the state, will commence by May this year, officials said on Sunday.

The plant at the Biotech Park in Andharua near here will have a capacity to produce 2.4 crore doses of different vaccines per day, they said.

At full capacity, this facility will be the biggest vaccine-producing plant in the country, the Chief Minister’s Office (CMO) said in a statement.

It is expected to produce over 15 vaccines for various diseases, including cholera and malaria.

The Rs 1,500-crore vaccine plant will create direct employment for 1,500 people, with most of them being local recruits, the CMO said.

The variety of vaccines produced in Bhubaneswar will be supplied to many parts of the world, it added.

V K Pandian, the chairman of ‘5T’ technology-led transformative initiatives on Sunday visited the sub-units and interacted with the management and employees. He urged all government agencies to assist in the commissioning of the plant within the next three months.

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre